Arotinoid ethyl ester (Ro 13-6298): a long term pilot study in various dermatoses

Area of Science:

• Dermatology
• Pharmacology
• Retinoid Research

Background:

• Retinoids are crucial in treating various skin conditions.
• Third-generation retinoids offer improved potency and selectivity.
• Etretinate has been a standard treatment, but with limitations.

Purpose of the Study:

• To evaluate the efficacy and safety of arotinoid ethyl ester Ro 13-6298.
• To compare its therapeutic profile with existing retinoids like etretinate.
• To assess potential advantages regarding toxicity and metabolic side effects.

Main Methods:

• An open, uncontrolled trial involving 57 patients with psoriasis and other severe skin disorders.
• Treatment with daily doses of Ro 13-6298 ranging from 20 to 150 micrograms.
• Monitoring patients for clinical response and adverse effects over 1 to 130 weeks.

Main Results:

• Ro 13-6298 demonstrated clinical activity and mucocutaneous side effects comparable to etretinate.
• One patient developed diffuse idiopathic skeletal hyperostosis after prolonged therapy.
• No significant increases in serum triglycerides or cholesterol were observed, even with long-term treatment.

Conclusions:

• Ro 13-6298 is a potent retinoid with a therapeutic spectrum similar to etretinate.
• Its lack of impact on lipid profiles may be a significant advantage.
• Potent mucocutaneous effects do not necessarily correlate with all other retinoid toxicities.